Schonfeld Strategic Advisors LLC Invests $1.52 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Schonfeld Strategic Advisors LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 72,980 shares of the biopharmaceutical company’s stock, valued at approximately $1,523,000. Schonfeld Strategic Advisors LLC owned 0.06% of Catalyst Pharmaceuticals at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC lifted its position in Catalyst Pharmaceuticals by 129.4% during the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock worth $4,939,000 after acquiring an additional 140,129 shares during the last quarter. Franklin Resources Inc. grew its holdings in Catalyst Pharmaceuticals by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 1,967 shares in the last quarter. JPMorgan Chase & Co. increased its position in Catalyst Pharmaceuticals by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after buying an additional 33,888 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 25.5% during the fourth quarter. CWA Asset Management Group LLC now owns 33,698 shares of the biopharmaceutical company’s stock worth $703,000 after buying an additional 6,853 shares in the last quarter. Finally, Oliver Luxxe Assets LLC boosted its position in shares of Catalyst Pharmaceuticals by 103.5% in the fourth quarter. Oliver Luxxe Assets LLC now owns 69,250 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 35,225 shares during the period. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $32.29.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $23.06 on Wednesday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The business has a fifty day moving average price of $22.95 and a two-hundred day moving average price of $22.36. The stock has a market capitalization of $2.81 billion, a PE ratio of 19.54, a PEG ratio of 3.31 and a beta of 0.70.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.